Yiziphi ezinye izindlela ezijojwayo zama-Statins?

-Delile

• Mayelana ne-PCSK9 Inhibitors
• Ukwelashwa Okusha Kakhulu
• Ucwaningo lwakamuva
• Izindleko
• Ikusasa le-PCSK9 Inhibitors

Ngokusho kuka-, abantu ababalelwa ku-610,000 babulawa yisifo senhliziyo e-United States minyaka yonke. Isifo senhliziyo siyimbangela ehamba phambili yokufa kwabesilisa nabesifazane.

Njengoba i-cholesterol ephezulu iyinkinga esabalele kangaka, imishanguzo emisha ibisemsebenzini ukusiza ukuyilawula nokuyiphatha. Ama-PCSK9 inhibitors awumugqa omusha wemithi empini yokulwa nesifo senhliziyo.

Lezi zidakamizwa ezijova ngokwehlisa i-cholesterol zisebenza ukukhulisa ikhono lesibindi sakho lokususa i-cholesterol "embi" ye-LDL egazini lakho futhi ngaleyo ndlela yehlise ingozi yokuhlaselwa yisifo senhliziyo noma isifo sohlangothi.

Qhubeka ufunde ukuze uthole okwamuva kuma-PCSK9 inhibitors, nokuthi angakusiza kanjani.

Mayelana ne-PCSK9 Inhibitors

Ama-PCSK9 inhibitors angasetshenziswa ngokufaka i-statin noma ngaphandle kwayo, kepha angasiza ekwehliseni i-cholesterol ye-LDL ngamaphesenti angama-75 uma isetshenziswa kanye nomuthi we-statin.

Lokhu kungaba lusizo ikakhulukazi kulabo abangakwazi ukubekezelela ubuhlungu bemisipha neminye imiphumela emibi yama-statins noma labo abangenakukwazi ukulawula i-cholesterol yabo ngokusebenzisa ama-statins kuphela.

Umthamo wokuqala onconywayo ujojowe i-75 mg kanye njalo emavikini amabili. Lesi silinganiso singakhuphukela ku-150 mg njalo emavikini amabili uma udokotela wakho ezwa ukuthi amazinga akho e-LDL awaphenduli ngokwanele emthamo omncane.

Ngenkathi imiphumela yocwaningo nokuhlolwa ngale mithi yokujova iseyintsha, ikhombisa ithemba elikhulu.

Ukwelashwa Okusha Kakhulu

I-Praluent (alirocumab) ne-Repatha (evolocumab) esanda kuvunywa, okuyindlela yokuqala yokwelapha i-cholesterol ekwehliseni umjovo ekilasini elisha lama-PCSK9 inhibitors. Ziklanyelwe ukusetshenziswa ngokuhlanganiswa ne-statin therapy kanye nezinguquko zokudla.

Okubalulekile kanye nokuphindisela okwabantu abadala abane-heterozygous family hypercholesterolemia (HeFH), isimo esizuzwe njengefa esidala amazinga aphezulu e-cholesterol ye-LDL egazini, nalabo abanesifo somtholampilo senhliziyo.

Le mithi ingamasosha omzimba akhomba iprotheni emzimbeni ebizwa nge-PCSK9. Ngokuvimbela ikhono le-PCSK9 lokusebenza, la ma-antibody akwazi ukususa i-cholesterol ye-LDL egazini futhi anciphise amazinga e-LDL cholesterol jikelele.

Ucwaningo lwakamuva

Izilingo nocwaningo kukhombise imiphumela emihle kubo bobabili Ababalulekile kanye noRepatha. Esivivinyweni sakamuva seRepatha, ababambiqhaza abane-HeFH nabanye abanezinto ezinobungozi obukhulu bokuhlaselwa yisifo senhliziyo noma isifo sohlangothi kwehlise i-cholesterol yabo ye-LDL ngokwesilinganiso se-.

Imiphumela emibi kakhulu ebikiwe ye-Repatha yile:

• ukutheleleka okuphezulu okuphefumulayo
• nasopharyngitis
• ukuhlungu obusemhlane
• umkhuhlane
• ukulinyazwa, ukubomvu, noma ubuhlungu endaweni yokujova

Ukuphendula okwaliwa, kufaka phakathi isifuba nokuqubuka, nakho kwabonwa.

Elinye icala elisebenzisa uPrueent nalo likhombise imiphumela emihle. Laba bahlanganyeli, abebevele besebenzisa ukwelashwa kwe-statin futhi beba ne-HeFH noma ingozi eyengeziwe yokushaywa unhlangothi noma isifo senhliziyo, babone ukwehla kwe-cholesterol ye-LDL.

Ukusetshenziswa okuyigugu kwakufana neRepatha, kufaka phakathi:

• ubuhlungu nokulimala endaweni yomjovo
• izimpawu ezinjengomkhuhlane
• nasopharyngitis
• ukusabela okweqile, njenge-hypersensitivity vasculitis

Izindleko

Njengoba kunjalo ngentuthuko eminingi yezemithi, le mithi emisha yokujova izofika nenani lentengo ephezulu. Ngenkathi izindleko zeziguli zizoya ngohlelo lwazo lomshuwalense, izindleko ezidayiswayo ziqala ku- $ 14,600 ngonyaka.

Uma kuqhathaniswa, izidakamizwa zegama lomkhiqizo zibiza u- $ 500 kuya ku- $ 700 kuphela ngonyaka, futhi lezo zibalo zehla kakhulu uma uthenga ifomu lama-generic statin.

Abahlaziyi balindele ukuthi le mishanguzo ithuthuke iye kwizinga lokuthengisa kakhulu ngesikhathi sokurekhoda futhi ingenise izigidigidi zamaRandi ekuthengisweni okusha.

Ikusasa le-PCSK9 Inhibitors

Ukuhlolwa kusaqhubeka ngokusebenza kwale mithi yokujova. Ezinye izikhulu zezempilo zikhathazeka ngokuthi izidakamizwa ezintsha zibeka amathuba ezingozi ze-neurocognitive, ngenxa yabahlanganyeli abathile bocwaningo ababika ubunzima ngokudideka nokungakwazi ukunaka.

Izilingo ezinkulu zomtholampilo zizophothulwa ngo-2017. Kuze kube yileso sikhathi ochwepheshe banxusa ukuqapha njengoba ukuhlolwa okwenziwe kuze kube manje kube okwesikhashana, okwenza kungacaci ukuthi ngabe ama-PCSK9 inhibitors angayinciphisa ngempela yini ingozi yesifo senhliziyo futhi andise izimpilo.